ClinicalTrials.gg
CompletedNCT01767675Updated Oct 2, 2026Results posted

Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Phase 2 interventional study of Secondary Cytoreductive Surgery and Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer, Fallopian Tubes Cancer and Peritoneal Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Completed at 11 sites in United States. Open to female participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment

How we know

Updated Oct 2, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
21 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Ovarian Neoplasms by Memorial Sloan Kettering Cancer Center — 5 open to participants now, 16 under way, 2 of them phase 3. Ovarian Neoplasms · Memorial Sloan Kettering Cancer Center.

Enrollment
12th of 49
99 · median 36
Started
2013
with 1 other
Phase 2
27 of 80
3 open now
Registered
57th of 80
by date

Among the 80 studies in Ovarian Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 12th largest by enrollment of the 49 interventional ones that give a count, is one of 2 that started in 2013, is one of 27 in phase 2, and was the 57th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

5 of the 80 studies in Ovarian Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 21 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Ovarian Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The purpose of this study is to see if the investigators can improve the treatment of this type of cancer. They want to find out what effects, good and/or bad, giving heated chemotherapy into the belly, known as hyperthermic intraperitoneal chemotherapy (HIPEC), has on the patient and this type of cancer.

The goal of HIPEC is to expose any cancer left in the abdomen after surgery to high doses of chemotherapy. The chemotherapy is heated in the hope that this will make it easier for it to get into and kill the cancer cells. The drug used for HIPEC will be carboplatin, a Food and Drug Administration (FDA) approved drug for use in ovarian, fallopian tube or primary peritoneal cancer.

03

Conditions studied

  • Ovarian Cancer
  • Fallopian Tubes Cancer
  • Peritoneal Cancer

Keywords

  • Secondary Cytoreductive Surgery
  • Carboplatin
  • Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
  • 12-275
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Inclusion Criteria for Eligibility Prior to Surgery:

  • Age ≥ 21 years old.
  • Patients with histologic diagnosis of epithelial ovarian carcinoma, primary peritoneal carcinoma, or fallopian tube carcinoma that has recurred >6 months since platinum-based chemotherapy (first recurrence) and who are scheduled for secondary surgical evaluation/cytoreduction.
  • Histologic epithelial cell types include serous, endometrioid, clear cell, or undifferentiated carcinomas, transitional cell carcinoma, mixed epithelial carcinoma, malignant Brenner's tumor, or adenocarcinoma N.O.S.
  • Performance Status (KPS) of ≥ 70%.
  • Disease-free interval ≤ 30 months.
  • No prior chemotherapy in the recurrent setting. Prior hormonal therapy is permitted. Concomitant anti-neoplastic anti-hormonal therapy (including tamoxifen, aromatase inhibitors etc.) is not allowed for patients participating in study treatment. Low-dose (physiologic) estrogen hormone-replacement therapy (HRT) may be given.
  • Patients receiving maintenance biologic therapy are eligible, provided their recurrence is documented more than 6 months from completion of primary cytotoxic chemotherapy (includes maintenance chemotherapy) and a minimum of 3 weeks has elapsed since their last infusion of biologic therapy at the start of protocol intervention, day 1.
  • Patients must be, after evaluation by the investigator, appropriate candidates for the administration of 5 to 6 cycles of standard platinum-based combination chemotherapy (carboplatin and paclitaxel, carboplatin and liposomal doxorubicin, or carboplatin and gemcitabine) following CRS with or without HIPEC.
  • Bone marrow function:
  • ≥ 8.5 g/dL.
  • (ANC) ≥ 1,000/mm3.
  • ≥ 100,000/mm3.
  • Renal function:
  • Creatinine ≤ 1.5mg/dl
  • Hepatic function:
  • ≤ 1.5 times .
  • ≤ 3 times the ULN.
  • AST ≤ 3 times the ULN.
  • Neurologic function:
  • Peripheral neuropathy ≤ CTC AE grade 2.
  • Blood coagulation parameters:
  • PT with an of ≤ 1.5 and a PTT ≤ 1.5 times the ULN. For patients on full-dose oral anti-coagulation (such as warfarin or rivaroxaban), in-range INR (usually between 2 and 3) and a PTT \<1.2 times the ULN.
  • Patients of must have a negative serum pregnancy test within 2 weeks prior to CRS and must be practicing an effective form of during the study period.

Inclusion Criteria for Eligibility Post-Surgery:

  • Patients will be consented prior to the surgical evaluation/cytoreductive surgery. Patients must have less than or equal to 0.5cm residual disease at the completion of the secondary surgery to be eligible for the study.

Exclusion Criteria:

Exclusion Criteria for Eligibility Prior to Surgery:

  • Tumors of low malignant potential (borderline carcinomas).
  • Subjects who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded.
  • Patients with a history of primary endometrial cancer are excluded unless the following conditions are met:
  • Stage not greater than IA.
  • Not a poorly differentiated subtype (including papillary serous, clear cell or other FIGO grade 3 lesions)
  • With the exception of non-melanoma skin cancer and other specific as noted above, subjects with other invasive malignancies, who had any evidence of the other cancer present within the last 1 year or whose previous cancer treatment contraindicates this protocol therapy, are excluded.
  • Subjects with known active acute hepatitis.
  • Subjects with active infection that requires parenteral antibiotics.
  • Active coronary artery disease (defined as unstable angina or a positive cardiac stress test).
  • Patients with a history of coronary artery disease may be included if they have had a normal stress test within 30 days of enrollment.
  • Uncontrolled hypertension defined as > 140/90 and not cleared for surgery at the time of consent..
  • (NYHA) Class II or higher Congestive heart failure.
  • History of cerebrovascular disease.
  • Immune deficiency: primary or acquired immune deficiency (i.e. AIDS or on medication after organ transplant).
  • Patients with other concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or places them at an unacceptable risk for participation in the study.
  • Patients with known carboplatin or cisplatin allergy.
  • \< 12 weeks.

Exclusion Criteria for Eligibility Post-Surgery:

  • Evidence of extensive intraperitoneal adhesions at the time of surgery, as determined by the operating surgeon which prohibits intraperitoneal therapy.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    Secondary Cytoreductive Surgery with HIPEC

    secondary cytoreductive surgery (CRS) with or without carboplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic combination chemotherapy for recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Patients will be randomized intraoperatively to undergo CRS with HIPEC (arm A) or CRS only (arm B) in a manner 1:1. Both arms will receive a standard platinum-based systemic chemotherapy postoperatively (5 cycles in arm A and 6 cycles in arm B). In some patients randomized to HIPEC at MSKCC only , peritoneal fluid and blood samples will be drawn before, during and after the HIPEC procedure.

    Procedure: Secondary Cytoreductive Surgery · Drug: Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) · Drug: platinum-based systemic chemotherapy postoperatively

  • Experimental
    Secondary Cytoreductive Surgery without HIPEC

    secondary cytoreductive surgery (CRS) with or without carboplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic combination chemotherapy for recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Patients will be randomized intraoperatively to undergo CRS with HIPEC (arm A) or CRS only (arm B) in a manner 1:1. Both arms will receive a standard platinum-based systemic chemotherapy postoperatively (5 cycles in arm A and 6 cycles in arm B).

    Procedure: Secondary Cytoreductive Surgery · Drug: platinum-based systemic chemotherapy postoperatively

Interventions

  • ProcedureSecondary Cytoreductive Surgery
  • DrugCarboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
  • Drugplatinum-based systemic chemotherapy postoperatively

    5 cycles

  • Drugplatinum-based systemic chemotherapy postoperatively

    6 cycles

06

What researchers measure

Primary outcomes

  1. Progression Free Survival

    A proportion of patients ≥ 40%, who are without evidence of disease progression at 24 months, is considered acceptable, whereas a proportion of ≤ 25% is considered not acceptable in this patient population.

    Time frame: up to 4 years

Secondary outcomes

  1. Number of Participants Evaluated for Toxicity

    Study participants will be evaluated for toxicity with the NCI Common Terminology Criteria for Adverse Events version 4.0. and MSKCC Surgical Secondary Events Grading System for complications.

    Time frame: 4 weeks post op

  2. Determine the Completion Rate of Four Cycles

    A secondary analysis of estimating the completion rate will be conducted. The completion rate and a 95% confidence interval will be calculated for each arm separately. Completion is defined as patients being able to complete ≥ 4 out of 5 or 6 cycles of a standard systemic chemotherapy.

    Time frame: 5 years

  3. Pharmacokinetics for HIPEC Arm Only

    in a subset of patients randomized to receive HIPEC in the OR. In patients randomized to HIPEC, peritoneal fluid and blood samples only from MSKCC patients will be drawn before, during and after the HIPEC procedure.

    Time frame: 5 years

07

Results

Posted Oct 2, 2026

Participant flow

Participant flow — Overall Study
MilestoneSecondary Cytoreductive Surgery With HIPECSecondary Cytoreductive Surgery Without HIPEC
Started4950
Completed4949
Not completed01
Withdrew: Removed (started maintenance therapy)01

Outcome measures

PrimaryProgression Free Survival

A proportion of patients ≥ 40%, who are without evidence of disease progression at 24 months, is considered acceptable, whereas a proportion of ≤ 25% is considered not acceptable in this patient population.

Time frame:
up to 4 years
Reported as:
Median · months
Progression Free Survival
monthsSecondary Cytoreductive Surgery With HIPECSecondary Cytoreductive Surgery Without HIPEC
Progression Free Survival16.3 (7.6 to 27.9)28.3 (16.5 to 41.3)
SecondaryNumber of Participants Evaluated for Toxicity

Study participants will be evaluated for toxicity with the NCI Common Terminology Criteria for Adverse Events version 4.0. and MSKCC Surgical Secondary Events Grading System for complications.

Time frame:
4 weeks post op
Reported as:
Count of participants · Participants
Number of Participants Evaluated for Toxicity
ParticipantsSecondary Cytoreductive Surgery With HIPECSecondary Cytoreductive Surgery Without HIPEC
Number of Participants Evaluated for Toxicity4949
SecondaryDetermine the Completion Rate of Four Cycles

A secondary analysis of estimating the completion rate will be conducted. The completion rate and a 95% confidence interval will be calculated for each arm separately. Completion is defined as patients being able to complete ≥ 4 out of 5 or 6 cycles of a standard systemic chemotherapy.

Time frame:
5 years
Reported as:
Count of participants · Participants
Determine the Completion Rate of Four Cycles
ParticipantsSecondary Cytoreductive Surgery With HIPECSecondary Cytoreductive Surgery Without HIPEC
Completed assigned postoperative platinum-based chemotherapy4646
Did not complete assigned postoperative platinum-based chemotherapy33
SecondaryPharmacokinetics for HIPEC Arm Only

in a subset of patients randomized to receive HIPEC in the OR. In patients randomized to HIPEC, peritoneal fluid and blood samples only from MSKCC patients will be drawn before, during and after the HIPEC procedure.

Time frame:
5 years
Reported as:
Geometric mean · ug/mL
Pharmacokinetics for HIPEC Arm Only
ug/mLSecondary Cytoreductive Surgery With HIPECSecondary Cytoreductive Surgery Without HIPEC
Max unfiltrable platinum concentrations in the peritoneum140 ± 1.28—
Max unfiltrable platinum concentrations in the plasma16.7 ± 1.24—
SecondaryPharmacokinetics for HIPEC Arm Only

in a subset of patients randomized to receive HIPEC in the OR. In patients randomized to HIPEC, peritoneal fluid and blood samples only from MSKCC patients will be drawn before, during and after the HIPEC procedure.

Time frame:
5 years
Reported as:
Geometric mean · ug h/mL
Pharmacokinetics for HIPEC Arm Only
ug h/mLSecondary Cytoreductive Surgery With HIPECSecondary Cytoreductive Surgery Without HIPEC
AUC total platinum in the peritoneum221 ± 1.26—
AUC total platinum in the plasma101 ± 1.33—

Adverse events

Collected over 30 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Secondary Cytoreductive Surgery With HIPEC20/49 (40.8%)17/49 (34.7%)17/49 (34.7%)
Secondary Cytoreductive Surgery Without HIPEC21/50 (42%)7/50 (14%)19/50 (38%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventSecondary Cytoreductive Surgery With HIPECSecondary Cytoreductive Surgery Without HIPEC
Abdominal InfectionInfections and infestations3/490/50
IleusGastrointestinal disorders3/490/50
Abdominal painGastrointestinal disorders2/490/50
Platelet count decreasedInvestigations2/490/50
Pancreatic anastomotic leakInjury, poisoning and procedural complications2/490/50
AnemiaBlood and lymphatic system disorders1/492/50
DiarrheaGastrointestinal disorders1/490/50
Intraoperative urinary injuryInjury, poisoning and procedural complications1/490/50
SepsisInfections and infestations1/490/50
Thromboembolic eventVascular disorders1/490/50
Most frequent other events
Showing 10 of 20
Most frequent other events
EventSecondary Cytoreductive Surgery With HIPECSecondary Cytoreductive Surgery Without HIPEC
AnemiaBlood and lymphatic system disorders7/498/50
Urinary tract infectionInfections and infestations4/490/50
Abdominal infectionInfections and infestations2/490/50
IleusGastrointestinal disorders2/491/50
Noninfected intra-abdominal or thoracic fluid collectionGastrointestinal disorders1/492/50
Pleural effusionRespiratory, thoracic and mediastinal disorders1/492/50
Wound infectionInfections and infestations0/492/50
ColitisGastrointestinal disorders1/490/50
Colonic obstructionGastrointestinal disorders1/490/50
Deep vein thrombosisVascular disorders1/490/50

Baseline characteristics

Age, Continuous
Age, Continuous(years)Secondary Cytoreductive Surgery With HIPECSecondary Cytoreductive Surgery Without HIPECTotal
Median59 (39 to 74)58 (33 to 78)59 (33 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)Secondary Cytoreductive Surgery With HIPECSecondary Cytoreductive Surgery Without HIPECTotal
Female495099
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Secondary Cytoreductive Surgery With HIPECSecondary Cytoreductive Surgery Without HIPECTotal
Hispanic or Latino347
Not Hispanic or Latino444387
Unknown or Not Reported235
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Secondary Cytoreductive Surgery With HIPECSecondary Cytoreductive Surgery Without HIPECTotal
American Indian or Alaska Native000
Asian213
Native Hawaiian or Other Pacific Islander000
Black or African American314
White394584
More than one race000
Unknown or Not Reported538
Region of Enrollment
Region of Enrollment(Participants)Secondary Cytoreductive Surgery With HIPECSecondary Cytoreductive Surgery Without HIPECTotal
United States495099
08

Study locations

11 sites
  • Hartford Healthcare Cancer Institute @ Hartford Hospital
    Hartford, Connecticut 06102, United States
  • Baptist Health South Florida
    Miami, Florida 33143, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Memorial Sloan Kettering Basking Ridge
    Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth
    Middletown, New Jersey 07748, United States
  • Memorial Sloan Kettering Bergen
    Montvale, New Jersey 07645, United States
  • Memorial Sloan Kettering Commack
    Commack, New York 11725, United States
  • Memorial Sloan Kettering Westchester
    Harrison, New York 10604, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Memorial Sloan Kettering Nassau (All protocol activities, except surgery)
    Uniondale, New York 11553, United States
09

References and documents

Publications

  • Zivanovic O, Chi DS, Zhou Q, Iasonos A, Konner JA, Makker V, Grisham RN, Brown AK, Nerenstone S, Diaz JP, Schroeder ED, Langstraat CL, Paroder V, Lakhman Y, Soldan K, Su K, Gardner GJ, Andikyan V, Guo J, Jewell EL, Long Roche K, Troso-Sandoval T, Lichtman SM, Moukarzel LA, Dessources K, Abu-Rustum NR, Aghajanian C, Tew WP, Beumer J, Sonoda Y, O'Cearbhaill RE. Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study. J Clin Oncol. 2021 Aug 10;39(23):2594-2604. doi: 10.1200/JCO.21.00605. Epub 2021 May 21. PubMed 34019431 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2013 to primary completion in Aug 2025, 151 months.

Results were first posted in Oct 2026, 1 year 1 month after primary completion.

Of 229 non-industry phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 80. This study's 151 months is above that.

Counting every sponsor, half of 345 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2013
First posted
Jan 14, 2013
StartActual
Jan 8, 2013
Primary completionActual
Aug 26, 2025
CompletionActual
Aug 26, 2025
Results first posted
Oct 2, 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 2, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore determine the proportion of patients who are without evidence of disease progressionNow Progression Free SurvivalTime frame: 24 months → up to 4 years
Oct 2, 2026
Secondary outcomes
3 edited
What changed in the outcomes
  • EditeddetermineDetermine the completion rateCompletion Rate of four cyclesFour CyclesTime frame: 5 years
  • ChangedBefore pharmacokineticsNow Pharmacokinetics for HIPEC Arm OnlyTime frame: 5 years
  • ChangedBefore To determine the toxicity and postoperative complications rateNow Number of Participants Evaluated for ToxicityTime frame: 4 weeks post op
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore determine the proportion of patients who are without evidence of disease progressionNow Progression Free SurvivalTime frame: 24 months → up to 4 years
    Secondary outcomes 3 edited
    What changed in the outcomes
    • EditeddetermineDetermine the completion rateCompletion Rate of four cyclesFour CyclesTime frame: 5 years
    • ChangedBefore pharmacokineticsNow Pharmacokinetics for HIPEC Arm OnlyTime frame: 5 years
    • ChangedBefore To determine the toxicity and postoperative complications rateNow Number of Participants Evaluated for ToxicityTime frame: 4 weeks post op

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT01767675
Collaborators
Mayo Clinic, Baptist Health South Florida, Hartford HealthCare, University of Pittsburgh, University of Chicago
Responsible party
Sponsor
First posted
Jan 14, 2013
Start date
Jan 8, 2013
Primary completion
Aug 26, 2025
Completion
Aug 26, 2025
Results posted
Oct 2, 2026
Last update
Oct 2, 2026

Study contacts

Dennis Chi, MD
principal investigator · Memorial Sloan Kettering Cancer Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion